bioAffinity Technologies, Inc. Debt Conversion, Original Debt, Amount
bioAffinity Technologies, Inc. (BIAF) reported Debt Conversion, Original Debt, Amount of $16.07 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-04-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionOriginalDebtAmount1 · last filed 2024-04-01
- bioAffinity Technologies, Inc. debt conversion, original debt, amount for the quarter ending 2022-12-31 was $0.00.
- bioAffinity Technologies, Inc. debt conversion, original debt, amount for fiscal 2022 was $16.07M.
| Period end | Debt Conversion, Original Debt, Amount 3 month | Debt Conversion, Original Debt, Amount 9 month | Debt Conversion, Original Debt, Amount 12 month |
|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $16.07M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $16.07M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |